Document is current
Any future updates will be listed below
-
Authors
Laitila, Tuomas https://orcid.org/0009-0000-1032-3303
Sankilampi, Ulla https://orcid.org/0000-0002-0789-9720
Renko, Marjo https://orcid.org/0000-0003-0507-4773
Kokki, Merja https://orcid.org/0000-0003-1501-7537
Ranta, Veli-Pekka https://orcid.org/0009-0007-5992-5517
-
Funding
Funding for this research was provided by:
Itä-Suomen Yliopisto (12024)
University of Eastern Finland
- License Information
-
More Information
Article History
Accepted: 29 September 2024
First Online: 22 October 2024
Declarations
:
: Financial support was received from the School of Pharmacy of the University of Eastern Finland.
: V.P.R. suggested Mediware adding the Jacqz-Aigrain and Dao models in the MwPharm++ software, and he has paid the academic license fee. Other authors have no relevant financial or non-financial interests to disclose.
: This retrospective study was approved by the Research Ethics Committee of Northern Savo, Kuopio, Finland (No 637/2018; April 24th 2018) and the Medical Director of Kuopio University Hospital (No 114/2019; September 27th 2019).
: Not applicable (routine clinical data analysed retrospectively).
: Not applicable.
: Data are not available based on the regulations of Kuopio University Hospital.
: Not applicable.
: T.L., U.S., M.R., M.K., and V.P.R. contributed to the study design. Data collection and analysis were performed by T.L. and V.P.R. The first draft of the manuscript was written by V.P.R. and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
